keyword
MENU ▼
Read by QxMD icon Read
search

RRMS

keyword
https://www.readbyqxmd.com/read/27921221/safety-and-efficacy-of-natalizumab-in-japanese-patients-with-relapsing-remitting-multiple-sclerosis-open-label-extension-study-of-a-phase-2-trial
#1
Takahiko Saida, Jun-Ichi Kira, Shuji Kishida, Takashi Yamamura, Nobuhisa Ohtsuka, Yan Ling, Shinichi Torii, Nisha Lucas, Geoffrey Kuesters, Deb Steiner, J T Tibung
INTRODUCTION: The efficacy of natalizumab was evaluated in Japanese patients with relapsing-remitting multiple sclerosis (RRMS) in a 24-week, phase 2 bridging study. An open-label, 2-year extension study from this trial was conducted to assess the safety and efficacy of natalizumab treatment in Japanese patients. METHODS: A total of 97 patients (43 previously on placebo; 54 previously on natalizumab) who had completed the bridging study were treated with 300 mg natalizumab every 4 weeks...
December 5, 2016: Neurology and Therapy
https://www.readbyqxmd.com/read/27920149/mir-142-3p-is-a-key-regulator-of-il-1%C3%AE-dependent-synaptopathy-in-neuroinflammation
#2
Georgia Mandolesi, Francesca De Vito, Alessandra Musella, Antonietta Gentile, Silvia Bullitta, Diego Fresegna, Helena Sepman, Claudio Di Sanza, Nabila Haji, Francesco Mori, Fabio Buttari, Emerald Perlas, Maria Teresa Ciotti, Eran Hornstein, Irene Bozzoni, Carlo Presutti, Diego Centonze
: MicroRNAs (miRNA) play an important role in posttranscriptional gene regulation of several physiological and pathological processes. In multiple sclerosis (MS), a chronic inflammatory and degenerative disease of the CNS, and in its mouse model, the experimental autoimmune encephalomyelitis (EAE), miRNA dysregulation has been mainly related to immune system dysfunction and white matter pathology. However, little is known about their role in grey matter pathology. Here, we explored miRNA involvement in the inflammation-driven alterations of synaptic structure and function, collectively known as synaptopathy, a neuropathological process contributing to excitotoxic neurodegeneration in MS/EAE...
December 5, 2016: Journal of Neuroscience: the Official Journal of the Society for Neuroscience
https://www.readbyqxmd.com/read/27919507/predictors-of-long-term-interferon-discontinuation-in-newly-diagnosed-relapsing-multiple-sclerosis
#3
Marcello Moccia, Raffaele Palladino, Antonio Carotenuto, Cinzia Valeria Russo, Maria Triassi, Roberta Lanzillo, Vincenzo Brescia Morra
BACKGROUND: Interferon-β has long-term safety and efficacy profiles for Relapsing Remitting Multiple Sclerosis (RRMS). However, the increasing number of available treatments requires to improve patient profiling and to perform individualized clinical decisions. Therefore, the present study investigated predictors of Interferon-β discontinuation. METHODS: The present retrospective observational cohort study included 499 newly diagnosed, drug naïve RRMS subjects receiving Interferon-β as first disease modifying treatment (DMT), during a 7...
November 2016: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/27919506/heart-rate-variability-predicts-the-magnitude-of-heart-rate-decrease-after-fingolimod-initiation
#4
Sakari Simula, Tomi P Laitinen, Tiina M Laitinen, Päivi Hartikainen, Juha Ek Hartikainen
BACKGROUND: Fingolimod is an immunomodulator with a disease modifying effect on relapsing-remitting multiple sclerosis (RRMS). A heart rate (HR) decrease shortly after fingolimod initiation, however, requires a clinical vigilance. The aim of this study was to prospectively investigate whether cardiac autonomic regulation can predict the magnitude of HR decrease after fingolimod initiation. METHODS: Twenty-five patients with RRMS underwent ambulatory 24-h electrocardiogram recording to assess HR variability 20±16 days before fingolimod initiation (baseline) and repeated at the day of fingolimod initiation to assess the magnitude of HR decrease...
November 2016: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/27919501/soluble-serum-vcam-1-whole-blood-mrna-expression-and-treatment-response-in-natalizumab-treated-multiple-sclerosis
#5
E R Petersen, H B Søndergaard, A B Oturai, Peh Jensen, P S Sorensen, F Sellebjerg, L Börnsen
BACKGROUND: Natalizumab reduces disease activity in multiple sclerosis (MS). Natalizumab binds to the very late antigen-4 and inhibits vascular cell adhesion molecule-1 (VCAM-1)-mediated transmigration of immune cells across the blood-brain-barrier. This is associated with decreased serum concentrations of soluble (s)VCAM-1 and an altered composition of immune cell-subsets in the blood. OBJECTIVE: We aimed to examine if sVCAM-1 serum concentrations and whole blood mRNA expression levels of immune activation biomarkers is associated with disease activity in natalizumab-treated MS-patients...
November 2016: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/27919496/cognitive-function-did-not-improve-after-initiation-of-natalizumab-treatment-in-relapsing-remitting-multiple-sclerosis-a-prospective-one-year-dual-control-group-study
#6
M Sundgren, Fredrik Piehl, Åke Wahlin, Tom Brismar
BACKGROUND: Cognitive impairment in multiple sclerosis (MS) is common and has severe implications. Natalizumab (NZ) has documented effects on relapse rate and radiological disease activity in relapsing-remitting MS (RRMS) but studies regarding its specific effects on cognitive functioning are few. Previous studies have reported improvement, however, often lacking relevant control groups. The objective of the present study was to evaluate the cognitive effects of NZ treatment, compared to patients on stable first-line treatment and healthy control subjects...
November 2016: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/27919495/clinical-characteristics-of-patients-with-multiple-sclerosis-enrolled-in-a-new-registry-in-egypt
#7
Magd Zakaria, Dina A Zamzam, Mohamed A Abdel Hafeez, Mahmoud S Swelam, Shaimaa S Khater, Mai F Fahmy, Ayman Abdel Hady, Mohamed M Fouad, Azza Abdel Nasser, Hany Aref, Mohsen Gadallah
BACKGROUND: Epidemiological studies of multiple sclerosis (MS) are lacking in Egypt. OBJECTIVE: To study the characteristics of Egyptian patients with multiple sclerosis in a new registry in a major tertiary referral centre in Cairo, Egypt. SUBJECT AND METHODS: Patients were from the project MS database of the Multiple Sclerosis Unit at Ain Shams University Hospitals (N=950). We conducted a detailed medical history and examination including the Expanded Disability Status Scale (EDSS)...
November 2016: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/27919484/vitamin-d-supplementation-reduces-relapse-rate-in-relapsing-remitting-multiple-sclerosis-patients-treated-with-natalizumab
#8
Julie Hejgaard Laursen, Helle Bach Søndergaard, Per Soelberg Sørensen, Finn Sellebjerg, Annette Bang Oturai
BACKGROUND: Vitamin D insufficiency is common among multiple sclerosis patients, and hypovitaminosis D has been associated with multiple sclerosis (MS) risk and disease activity. OBJECTIVE: To investigate how recommendations on vitamin D3 supplements affect 25-hydroxyvitamin D (25(OH)D) levels in patients with relapsing-remitting MS (RRMS) and to examine the clinical effects associated with changes in 25(OH)D levels. METHODS: In this prospective cohort study, baseline blood samples were collected from 170 natalizumab-treated RRMS patients during winter 2009-2010 and were repeated the following winter...
November 2016: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/27919195/efficacy-and-safety-of-mitoxantrone-use-in-primary-and-secondary-progressive-multiple-sclerosis-study-site-experience-based-on-the-therapy-of-104-patients
#9
Anetta Lasek-Bal, Karina Bartoszek, Arkadiusz Steposz, Przemyslaw Puz, Wieslaw Bal, Zofia Kazibutowska
Mitoxantrone (MX) is used in patients with primary and secondary progressive as well as relapsing-remitting type of multiple sclerosis (PPMS, SPMS, RRMS). The objective of our project was to evaluate the efficacy and safety of mitoxantrone use in patients with PPMS and SPMS. Methods The retrospective study included 104 patients (mean age 54.2 ± 9.0), with PPMS (13.46%) and SPMS (86.54%) treated with mitoxantrone. During single cycle of the MX therapy a dose of 12 mg/m2 of body surface area was administred and next cycles every three months up to a total dose of 140 mg/m2 were realized...
December 6, 2016: International Journal of Neuroscience
https://www.readbyqxmd.com/read/27918703/patterns-and-predictors-of-change-in-moderate-to-vigorous-physical-activity-over-time-in-multiple-sclerosis
#10
Rachel E Klaren, Jeffer E Sasaki, Edward McAuley, Robert W Motl
BACKGROUND: Physical inactivity is common in persons with multiple sclerosis (MS), but there is very little known about the pattern and predictors of changes in physical activity over time. PURPOSE: This study examined changes in moderate-to-vigorous physical activity (MVPA) over a 30-month time period and the demographic and clinical predictors of such changes in relapsing-remitting MS (RRMS). METHODS: 269 persons with MS wore an accelerometer for a 7-day period and completed a demographic/clinical scale every 6 months over a 30-month period...
December 5, 2016: Journal of Physical Activity & Health
https://www.readbyqxmd.com/read/27907914/anxiety-and-coping-strategy-changes-in-multiple-sclerosis-patients-initiating-fingolimod-the-grace-prospective-study
#11
Thibault Moreau, Catherine Bungener, Olivier Heinzlef, Laurent Suchet, Florent Borgel, Isabelle Bourdeix, Mohamed Meite, Karin Rerat, Isabelle Chouette
The objective of this prospective study was to assess the changes in anxiety levels, and their relationship with coping strategies over the first four months of fingolimod treatment in patients with relapsing remitting multiple sclerosis (RRMS). Data were collected at the inclusion visit (Visit 1) and 4 months later (Visit 2). We used the Hospital Anxiety and Depression Scale (HADS) to assess the level of anxiety and the Coping Inventory for Stressful Situations scale to assess the coping strategies used when engaged with stressful situations...
December 2, 2016: European Neurology
https://www.readbyqxmd.com/read/27892723/optimization-and-stratification-of-multiple-sclerosis-treatment-in-fast-developing-economic-countries-a-perspective-from-qatar
#12
Dirk Deleu, Boulenouar Mesraoua, Hisham El Khider, Beatriz Canibano, Gayane Melikyan, Hassan Al Hail, Noha Mhjob, Anjushri Bhagat, Faiza Ibrahim, Yolande Hanssens
OBJECTIVE: The introduction of disease-modifying therapies (DMTs) - with varying degrees of efficacy for reducing annual relapse rate and disability progression - has considerably transformed the therapeutic landscape of relapsing-remitting multiple sclerosis (RRMS). We aim to develop rational evidence-based treatment recommendations and algorithms for the management of clinically isolated syndrome (CIS) and RRMS conform to the healthcare system in a fast-developing economic country such as Qatar...
November 28, 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27888416/lesion-remyelinating-activity-of-gsk239512-versus-placebo-in-patients-with-relapsing-remitting-multiple-sclerosis-a-randomised-single-blind-phase-ii-study
#13
Caryl J Schwartzbach, Richard A Grove, Robert Brown, Debra Tompson, Florian Then Bergh, Douglas L Arnold
Histamine H3 receptor blockade may enhance lesion remyelination in multiple sclerosis (MS). The efficacy (using a magnetic resonance imaging marker of myelination, magnetisation transfer ratio [MTR]), safety and pharmacokinetics of GSK239512, a potent and brain penetrant H3 receptor antagonist/inverse agonist on lesion remyelination in relapsing-remitting MS (RRMS) were assessed. This was a phase II, randomised, parallel-group, placebo-controlled, double-blind (sponsor-unblinded), international, multicentre study (NCT01772199)...
November 25, 2016: Journal of Neurology
https://www.readbyqxmd.com/read/27886183/fingolimod-therapeutic-mechanisms-and-ocular-adverse-effects
#14
REVIEW
P Mandal, A Gupta, W Fusi-Rubiano, P A Keane, Y Yang
Fingolimod is an oral immunomodulating drug used in the management of relapsing-remitting multiple sclerosis (RRMS). We aim to review the published literature on ocular manifestations of fingolimod therapy and their possible underlying mechanisms. The therapeutic effects of fingolimod are mediated via sphingosine receptors, which are found ubiquitously in various organs, including lymphoid cells, central nervous system, cardiac myocytes, and smooth muscle cells. Fingolimod-associated macular oedema (FAME) is the most common ocular side effect but retinal haemorrhages and retinal vein occlusion can occur...
November 25, 2016: Eye
https://www.readbyqxmd.com/read/27882837/determining-multiple-sclerosis-phenotype-from-electronic-medical-records
#15
Richard E Nelson, Jorie Butler, Joanne LaFleur, Kristin Knippenberg, Aaron W C Kamauu, Scott L DuVall
BACKGROUND: Multiple sclerosis (MS), a central nervous system disease in which nerve signals are disrupted by scarring and demyelination, is classified into phenotypes depending on the patterns of cognitive or physical impairment progression: relapsing-remitting MS (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS), or progressive-relapsing MS (PRMS). The phenotype is important in managing the disease and determining appropriate treatment. The ICD-9-CM code 340.0 is uninformative about MS phenotype, which increases the difficulty of studying the effects of phenotype on disease...
December 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27882532/alemtuzumab-use-in-clinical-practice-recommendations-from-european-multiple-sclerosis-experts
#16
Thomas Berger, Irina Elovaara, Sten Fredrikson, Chris McGuigan, Lucia Moiola, Kjell-Morten Myhr, Celia Oreja-Guevara, Igor Stoliarov, Uwe K Zettl
Alemtuzumab (Lemtrada™) is a humanized monoclonal antibody approved in more than 50 countries. Within the European Union, alemtuzumab is indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features; in the USA, the indication states that alemtuzumab should generally be reserved for the treatment of patients with relapsing forms of multiple sclerosis who have had an inadequate response to two or more disease-modifying therapies (DMTs)...
November 23, 2016: CNS Drugs
https://www.readbyqxmd.com/read/27880972/interferons-beta-versus-glatiramer-acetate-for-relapsing-remitting-multiple-sclerosis
#17
REVIEW
Loredana La Mantia, Carlo Di Pietrantonj, Marco Rovaris, Giulio Rigon, Serena Frau, Francesco Berardo, Anna Gandini, Anna Longobardi, Bianca Weinstock-Guttman, Alberto Vaona
BACKGROUND: Interferons-beta (IFNs-beta) and glatiramer acetate (GA) were the first two disease-modifying therapies (DMTs) approved 20 years ago for the treatment of multiple sclerosis (MS). DMTs' prescription rates as first or switching therapies and their costs have both increased substantially over the past decade. As more DMTs become available, the choice of a specific DMT should reflect the risk/benefit profile, as well as the impact on quality of life. As MS cohorts enrolled in different studies can vary significantly, head-to-head trials are considered the best approach for gaining objective reliable data when two different drugs are compared...
November 24, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27878760/reduced-plasma-levels-of-25-hydroxycholesterol-and-increased-cerebrospinal-fluid-levels-of-bile-acid-precursors-in-multiple-sclerosis-patients
#18
Peter J Crick, William J Griffiths, Juan Zhang, Martin Beibel, Jonas Abdel-Khalik, Jens Kuhle, Andreas W Sailer, Yuqin Wang
Multiple sclerosis (MS) is an autoimmune, inflammatory disease of the central nervous system (CNS). We have measured the levels of over 20 non-esterified sterols in plasma and cerebrospinal fluid (CSF) from patients suffering from MS, inflammatory CNS disease, neurodegenerative disease and control patients. Analysis was performed following enzyme-assisted derivatisation by liquid chromatography-mass spectrometry (LC-MS) exploiting multistage fragmentation (MS (n) ). We found increased concentrations of bile acid precursors in CSF from each of the disease states and that patients with inflammatory CNS disease classified as suspected autoimmune disease or of unknown aetiology also showed elevated concentrations of 25-hydroxycholestertol (25-HC, P < 0...
November 23, 2016: Molecular Neurobiology
https://www.readbyqxmd.com/read/27870963/ultra-hydrophobic-sticky-polymer-surfaces-formed-by-water-induced-surface-deformation
#19
Eun-Ho Sohn, Byoung Gak Kim, Hyunkee Hong, Da-Jung Sohn, Jong-Chan Lee
Surface properties of poly(oxyethylene)s with alkyl thioether side chains (CH3-nTE; n=carbon atoms in the side chain) were investigated. CH3-nTEs having shorter side chains (n=6, 8, 10) did not have ordered structures, while those with longer chains (n=12, 14) showed well-ordered, lamellar structures with side chain crystalline domains. Accordingly, CH3-12TE and CH3-14TE film surfaces were much more enriched with hydrophobic alkyl side chains than CH3-8TE and CH3-10TE surfaces. However, CH3-12TE and CH3-14TE films had smaller water contact angles (≈114°) than CH3-8TE and CH3-10TE films (>130°)...
November 9, 2016: Journal of Colloid and Interface Science
https://www.readbyqxmd.com/read/27829656/safety-and-efficacy-of-fingolimod-and-natalizumab-in-multiple-sclerosis-after-the-failure-of-first-line-therapy-single-center-experience-based-on-the-treatment-of-forty-four-patients
#20
Przemysław Puz, Anetta Lasek-Bal
BACKGROUND In Poland, natalizumab or fingolimod treatment can be delivered as a second-line therapy to those patients with relapsing-remitting multiple sclerosis (RRMS) who demonstrated no response to interferon or glatiramer acetate treatment for a minimum of one year. MATERIAL AND METHODS Analysis covered 44 RRMS patients switched from first- to second-line therapy. The annualized relapse rate, disability progression (assessed with Expanded Disability Status Scale, EDSS) and MRI results (new or enlarged T2 lesions and new Gd-positive lesions) before and after switching were compared...
November 10, 2016: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
keyword
keyword
33225
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"